Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases.
The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases.
The company has made significant scientific and development advances in its product pipeline and is developing a portfolio of point of care enzyme-based products designed to address the need for improved nutritional care in a number of medical conditions. Since starting operations in 2011, Alcresta Therapeutics has achieved significant corporate milestones, created an extensive intellectual property portfolio, optimized production capabilities, and developed exciting scientific data supporting its products and technology platform.
The company’s lead product, RELiZORB™, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA).
The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.